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Abstract 
Review on translocations in lung adenocarcinomas, 
with data on clinics, genetics and cytogenetics. 
Classification 
In the group of malignant epithelial tumours of the 
lungs, adenocarcinomas belong to the non-small 
cell carcinomas (non-small cell lung cancer 
(NSCLC)), as opposed to small cell carcinomas 
(SCLC). Other NSCLCs of the lungs are: squamous 
cell carcinomas, adenosquamous carcinomas, large 
cell carcinomas, sarcomatoid carcinomas, carcinoid 
tumours, and salivary gland tumours. 




KRAS (12p12) and EGFR (7p11) are mutated in 
15% and 10% of NSCLCs, and PIK3CA (3q26), 
BRAF (7q34), and ERBB2 (17q12) are mutated in 
another 5% of NSCLCs. The presence of EGFR or 
KRAS mutations and translocations such as 
EML4/ALK or other tyrosine kinase fusions (see 
below), are mutually exclusive in lung 
adenocarcinoma. 
Three tyrosine kinase receptors are recurrently 
found implicated in translocations: ALK (2p23), 
ROS1 (6q22), and RET (10q11). Kinase fusion 
positive (ALK, ROS1 and RET fusions) lung 
cancers are (almost) exclusively adenocarcinomas, 
at times squamous or adenosquamous carcinomas. 
In a study of 16 patients with adenocarcinoma and 
one patient with large cell carcinoma, never-
smokers have more often EGFR mutations or ALK-
ROS1-RET translocations and smokers more often 
KRAS, TP53, BRAF, JAK2, JAK3 and mismatch 
repair gene mutations (Govindan et al., 2012). 
Epidemiology 
Adenocarcinomas comprise 30% to 40% of lung 
cancers, with geographical variations, and it is 
becoming more prevalent. Tobacco smoking is the 
major cause of lung cancer of each histological 
subtype, but adenocarcinoma is more frequently 
found in non-smokers than any other histologic 
types of lung cancer. 
Clinics 
Adenocarcinomas are more common in the 
peripheral lung (alveolar or bronchioalveolar cell) 
than in central location, and the visceral pleura is 
therefore frequently involved, with fibrosis. 
Patients with ALK, ROS1, or RET fusion 
transcripts are often younger nonsmoking female 
patients, with early lymph node metastases. 
Pathology 
Presence of either solid signet ring cell or 
cribriform patterns with abundant extracellular 
mucus is frequently found in ALK-ROS1-RET 
translocations cases (Takeuchi et al., 2012; Yoshida 
et al., 2013). 
Genes 
- As said above, three membrane associated 
tyrosine kinase receptors are recurrently involved in 
translocations in adenocarcinomas: ALK, 
implicated with six possible different partners; 
ROS1, implicated with nine possible partners; RET, 
implicated with three possible partners. Other 
tyrosine kinases can also be involved (PDGFRA 
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(4q12), DDR1 (6p21), FGFR2 (10q26), AXL 
(19q13), ...). 
- Eight others genes were found implicated in two 
distinct translocations: APAF1 (12q23, structural 
core of the apoptosome), CCDC6 (10q21, structural 
constituent of the cytoskeleton), GOPC (6q22, ion 
channel binding protein), H19 (11p15, non-protein 
coding sequence), KDELR2 (7p22, receptor), 
KIF5B (10p11, motor protein), SFTPA2 and 
SFTPB (10q22 and 2p11, surfactant-associated 
proteins); 138 other genes were implicated once. 
Treatment 
Targeted therapies: the treatments for NSCLCs 
have shown impressive clinical responses in 
patients with EGFR mutations treated with EGFR 
tyrosine kinase inhibitor therapy. ALK and ROS1 
fusions proteins are both sensitive to treatment with 
the new ALK tyrosine kinase inhibitors, and 
clinical trials report an overall response rate of 57% 
in patients with ALK rearrangements. Cells 
expressing KIF5B/RET were found sensitive to 
multitargeted kinase inhibitors that inhibit RET. 
Therefore, more than 50% of the patients with lung 
adenocarcinoma may benefit from treatments with 
corresponding kinase inhibitors (Takeuchi et al., 
2012). 
Prognosis 
In a study of 248 patients with NSCLC, the 2-year 
overall survival rates were 89% for EGFR, 73% for 
KRAS, 74% for ALK, and 62% for RET. There 
was no significant difference between patients with 
RET-positive and RET-negative tumors. Patients 
with EGFR mutations had a significantly longer 
overall survival than patients with KRAS mutations 
(Wang et al., 2012). Patients lacking EGFR 
mutations or translocations involving tyrosine 




The most frequent ALK fusion in adenocarcinomas 
of the lung is EML4/ALK (4% to 7% of cases), and 
the second is KIF5B/ALK (0.5%). ROS1 fusions 
are found in 1% to 2.5% of patients with NSCLCs 
(Davies et al., 2012; Yoshida et al., 2013). RET 
fusions occur in 1.4% of NSCLCs and 1.7% of lung 
adenocarcinomas (Takeuchi et al., 2012; Yoshida et 
al., 2013). 
- ALK is implicated with six possible different 
partners: inv(2)(p21p23) or del(2)(p21p23) 
EML4/ALK, t(2;2)(p23;p22) STRN/ALK, 
t(2;3)(p23;q12) TFG/ALK, t(2;9)(p23;q31) 
ALK/PTPN3, t(2;10)(p23;p11) KIF5B/ALK and 
t(2;14)(p23;q32) KLC1/ALK; 
- ROS1 is implicated with nine possible partners:  
t(1;6)(q21;q22) TPM3/ROS1, t(4;6)(p15;q22) 
SLC34A2/ROS1, t(5;6)(q33;q22) CD74/ROS1, 
t(6;6)(q22;q22) GOPC/ROS1, inv(6)(q22q25) 
EZR/ROS1, t(6;7)(q22;p22) KDELR2/ROS1, 
t(6;10)(q22;q21) CCDC6/ROS1, t(6;12)(q22;q14) 
LRIG3/ROS1, and t(6;20)(q22;q12) SDC4/ROS1; 
- RET is implicated with three possible partners: 
inv(10)(p11q11) CCDC6/RET, inv(10)(p11q11) 
KIF5B/RET, and inv(10)(q11q11) NCOA4/RET. 
These translocations lead to aberrant tyrosine 
kinase activation. 
Cytogenetics Morphological 
The eighty six translocations reported so far in 
adenocarcinomas of the lung greatly differ from 
that ones found in squamous cell carcinoma, or that 
ones found in small cell carcinoma.  
They are the following: 
t(X;X)(p22;q13) EDA/MID1 (Seo et al., 2012) 
t(X;1)(q23;q24) ACSL4/DCAF6 (Govindan et al., 
2012) 
t(X;20)(p11;p12) SPTLC3/MAOA (Seo et al., 
2012) 
t(1;1)(p36;p36) UBR4/ATP13A2 (Seo et al., 2012) 
t(1;1)(p36;p34) ARHGEF16/TCTEX1D4 (Seo et 
al., 2012) 
t(1;1)(p35;p35) SRSF4/SNRNP40 (Seo et al., 2012) 
t(1;1)(p34;p32) FGGY/TESK2 (Majewski et al., 
2013) 
t(1;1)(p13;p12) IGSF3/MAN1A2 (Seo et al., 2012) 
t(1;1)(p13;p12) VANGL1/HAO2 (Govindan et al., 
2012) 
t(1;1)(q24;q24) CD247/GPR161 (Imielinski et al., 
2012) 
t(1;6)(p32;q14) ZFYVE9/CGA (Seo et al., 2012) 
t(1;6)(q21;q22) TPM3/ROS1 (Takeuchi et al., 
2012) 
t(1;19)(q23;p13) TCF3/PBX1 (Mo et al., 2013) 
t(2;2)(p23;p22) STRN/ALK (Majewski et al., 2013) 
inv(2)(p21p23) del(2)(p21p23) EML4/ALK 
(Rikova et al., 2007; Choi et al., 2008; Koivunen et 
al., 2008; Majewski et al., 2013) 
t(2;2)(p22;p21) MAP4K3/PRKCE (Seo et al., 
2012) 
t(2;2)(q21;q22) MGAT5/HNMT (Seo et al., 2012) 
t(2;2)(q24;q24) STK39/B3GALT1 (Imielinski et 
al., 2012) 
t(2;2)(q33;q33) ADAM23/SGOL2 (Imielinski et 
al., 2012) 
t(2;3)(p23;q12) TFG/ALK (Rikova et al., 2007) 
t(2;8)(p11;p21) SFTPB/DPYSL2 (Seo et al., 2012) 
t(2;9)(p23;q31) ALK/PTPN3 (Jung et al., 2012) 
t(2;10)(p23;p11) KIF5B/ALK (Takeuchi et al., 
2009; Wong et al., 2011) 
t(2;10)(p11;q22) SFTPA2/SFTPB (Seo et al., 2012) 
t(2;14)(p23;q32) KLC1/ALK (Togashi et al., 2012) 
t(2;19)(q11;q13) XRCC1/MAL (Seo et al., 2012) 
t(3;3)(p25;p25) TTLL3/MTMR14 (Imielinski et al., 
2012) 
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t(3;3)(p24;p24) EOMES/SLC4A7 (Imielinski et al., 
2012) 
t(3;3)(p21;p14) CACNA2D3/FLNB (Govindan et 
al., 2012) 
t(3;3)(q21;q22) MGLL/SLCO2A1 (Imielinski et al., 
2012) 
t(3;3)(q25;q25) CP/WWTR1 (Imielinski et al., 
2012) 
t(3;6)(p24;q16) UBE2E1/ASCC3 (Seo et al., 2012) 
t(4;6)(p15;q22) SLC34A2/ROS1 (Davies et al., 
2012; Rimkunas et al 2012; Seo et al., 2012; 
Takeuchi et al., 2012) 
t(4;12)(q12;q12) SCAF11/PDGFRA (Seo et al., 
2012) 
t(5;5)(q12;q12) ERBB2IP/MAST4 (Seo et al., 
2012) 
t(5;5)(q13;q13) ARHGEF28/UTP15 (Imielinski et 
al., 2012) 
t(5;5)(q31;q31) UBE2D2/MATR3 (Imielinski et al., 
2012) 
t(5;6)(q11;p22) IL6ST/KDM1B (Seo et al., 2012) 
t(5;6)(q33;q22) CD74/ROS1 (Rikova et al., 2007; 
Davies et al., 2012; Rimkunas et al., 2012; Seo et 
al., 2012) 
t(5;6)(q33;q22) ROS1/CD74 (Imielinski et al., 
2012) 
t(5;8)(p15;q22) CMBL/NDUFAF6 (Seo et al., 
2012; Takeuchi et al., 2012) 
t(5;10)(q35;q11) SGMS1/STK10 (Govindan et al., 
2012) 
t(5;12)(q33;q14) GRIP1/TNIP1 (Govindan et al., 
2012) 
t(6;6)(q22;q22) GOPC/ROS1 (Rimkunas et al., 
2012; Suehara et al., 2012) 
t(6;6)(q22;q22) TPD52L1/TRMT11 (Seo et al., 
2012) 
inv(6)(q22q25) EZR/ROS1 (Takeuchi et al., 2012; 
Yoshida et al., 2013) 
t(6;7)(q22;p22) KDELR2/GOPC (Govindan et al., 
2012) 
t(6;7)(q22;p22) KDELR2/ROS1 (Govindan et al., 
2012) 
t(6;10)(q22;q21) CCDC6/ROS1 (Seo et al., 2012) 
t(6;12)(q22;q14) LRIG3/ROS1 (Takeuchi et al., 
2012) 
t(6;12)(q24;q13-14) UTRN/OS9 (Seo et al., 2012) 
t(6;20)(q22;q12) SDC4/ROS1 (Davies et al., 2012; 
Takeuchi et al., 2012) 
t(9;9)(q34;q34) TUBB4B/COBRA1 (Imielinski et 
al., 2012) 
t(9;12)(p13;q23) APAF1/TLN1 (Govindan et al., 
2012) 
t(9;12)(p13;q23) APAF1/UNC13B (Govindan et 
al., 2012) 
inv(10)(p11q11) CCDC6/RET (Matsubara et al., 




inv(10)(p11q11) KIF5B/RET (Ju et al., 2012;  
Kohno et al., 2012; Lipson et al., 2012; Seo et al., 
2012; Suehara et al., 2012; Takeuchi et al., 2012; 
Wang et al., 2012) 
inv(10)(q11q11) NCOA4/RET (Wang et al., 2012) 
t(10;10)(q11;q11) MARCH8/PRKG1 (Govindan et 
al., 2012) 
t(10;10)(q25;q25) SHOC2/RBM20 (Imielinski et 
al., 2012) 
t(10;12)(q26;q24) FGFR2/CIT (Seo et al., 2012) 
t(10;19)(q22;q13) FTL/SFTPA2 (Seo et al., 2012) 
t(11;11)(q13;q13) RBM14/FGF3 (Seo et al., 2012) 
t(11;11)(q23;q23) HYOU1/C11ORF93 (Seo et al., 
2012) 
t(11;13)(q24;q14) APLP2/TNFSF11 (Seo et al., 
2012) 
t(11;14)(p15;q11) MMP14/H19 (Seo et al., 2012) 
t(11;19)(p15;p13) H19/CALR (Seo et al., 2012) 
t(12;12)(q13;q14) SLC16A7/MUCL1 (Seo et al., 
2012) 
t(12;12)(q15;q21) RAB21/FRS2 (Seo et al., 2012) 
t(12;12)(q23;q24) TXNRD1/GPR133 (Seo et al., 
2012) 
t(12;16)(p12;q23) KRAS/CDH13 (Seo et al., 2012) 
t(12;17)(q14;q25) RASSF3/TTYH2 (Govindan et 
al., 2012) 
t(14;19)(q13;q13) AXL/MBIP (Seo et al., 2012) 
t(15;15)(q22;q24) CYP1A2/SPG21 (Imielinski et 
al., 2012) 
t(15;22)(q21;q12) MCM5/TRPM7 (Majewski et al., 
2013) 
t(16;16)(p13;p13) MSLN/WDR90 (Majewski et al., 
2013) 
t(17;17)(p13;p13) XAF1/FAM64A (Seo et al., 
2012) 
t(17;17)(p12;p11) TTC19/ATPAF2 (Seo et al., 
2012) 
 
t(17;17)(q11;q12) IKZF3/NF1 (Majewski et al., 
2013) 
 
t(17;17)(q23;q23) BCAS3/MAP3K3 (Seo et al., 
2012) 
t(17;21)(q24;q22) BRWD1/CCDC46 (Seo et al., 
2012) 
t(18;18)(q11;q11) LAMA3/RIOK3 (Majewski et 
al., 2013) 
t(18;20)(p11;q13) PHACTR3/PTPRM (Imielinski 
et al., 2012) 
t(19;19)(p13;p13) MIER2/NMRK2 (Seo et al., 
2012) 
t(19;19)(p13;p13) OAZ1/SF3A2 (Imielinski et al., 
2012) 
t(19;19)(q13;q13) LSM14A/SIPA1L3 (Seo et al., 
2012) 
t(19;19)(q13;q13) RHPN2/ANKRD27 (Govindan  
et al., 2012) 
 






Atlas Genet Cytogenet Oncol Haematol. 2015; 19(4) 314 
References 
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, 
Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, 
Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan 
J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, 
Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb 
MJ. Global survey of phosphotyrosine signaling identifies 
oncogenic kinases in lung cancer. Cell. 2007 Dec 
14;131(6):1190-203 
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, 
Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, 
Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, 
Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of 
the transforming EML4-ALK fusion gene in non-small-cell 
lung cancer. Nature. 2007 Aug 2;448(7153):561-6 
Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, 
Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, 
Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita 
Y, Sugiyama Y, Ishikawa Y, Mano H. Identification of novel 
isoforms of the EML4-ALK transforming gene in non-small 
cell lung cancer. Cancer Res. 2008 Jul 1;68(13):4971-6 
Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits 
E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee 
J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, 
Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, 
Jänne PA. EML4-ALK fusion gene and efficacy of an ALK 
kinase inhibitor in lung cancer. Clin Cancer Res. 2008 Jul 
1;14(13):4275-83 
Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, 
Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, 
Okumura S, Nakagawa K, Ishikawa Y, Mano H. KIF5B-
ALK, a novel fusion oncokinase identified by an 
immunohistochemistry-based diagnostic system for ALK-
positive lung cancer. Clin Cancer Res. 2009 May 
1;15(9):3143-9 
Wong DW, Leung EL, Wong SK, Tin VP, Sihoe AD, Cheng 
LC, Au JS, Chung LP, Wong MP. A novel KIF5B-ALK 
variant in nonsmall cell lung cancer. Cancer. 2011 Jun 
15;117(12):2709-18 
Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, 
Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, 
Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-
Garcia M, Doebele RC. Identifying and targeting ROS1 
gene fusions in non-small cell lung cancer. Clin Cancer 
Res. 2012 Sep 1;18(17):4570-9 
Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, 
Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen 
K, Walker J, McDonald S, Bose R, Ornitz D, Xiong D, You 
M, Dooling DJ, Watson M, Mardis ER, Wilson RK. 
Genomic landscape of non-small cell lung cancer in 
smokers and never-smokers. Cell. 2012 Sep 
14;150(6):1121-34 
Imielinski M, Berger AH, Hammerman PS, Hernandez B, 
Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko 
A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, 
Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, 
Greulich H, Banerji S, Zander T, Seidel D, Leenders F, 
Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, 
Goparju C, Thompson K, Winckler W, Kwiatkowski D, 
Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, 
Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway 
LA, Getz G, Meyerson M. Mapping the hallmarks of lung 
adenocarcinoma with massively parallel sequencing. Cell. 
2012 Sep 14;150(6):1107-20 
Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim 
YT, Kim JI, Kang JH, Seo JS. A transforming KIF5B and 
RET gene fusion in lung adenocarcinoma revealed from 
whole-genome and transcriptome sequencing. Genome 
Res. 2012 Mar;22(3):436-45 
Jung Y, Kim P, Jung Y, Keum J, Kim SN, Choi YS, Do IG, 
Lee J, Choi SJ, Kim S, Lee JE, Kim J, Lee S, Kim J. 
Discovery of ALK-PTPN3 gene fusion from human non-
small cell lung carcinoma cell line using next generation 
RNA sequencing. Genes Chromosomes Cancer. 2012 
Jun;51(6):590-7 
Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, 
Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, 
Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, 
Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, 
Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda 
H, Yoshida T, Yokota J, Shibata T. KIF5B-RET fusions in 
lung adenocarcinoma. Nat Med. 2012 Feb 12;18(3):375-7 
Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, 
Jarosz M, Curran JA, Balasubramanian S, Bloom T, 
Brennan KW, Donahue A, Downing SR, Frampton GM, 
Garcia L, Juhn F, Mitchell KC, White E, White J, Zwirko Z, 
Peretz T, Nechushtan H, Soussan-Gutman L, Kim J, 
Sasaki H, Kim HR, Park SI, Ercan D, Sheehan CE, Ross 
JS, Cronin MT, Jänne PA, Stephens PJ. Identification of 
new ALK and RET gene fusions from colorectal and lung 
cancer biopsies. Nat Med. 2012 Feb 12;18(3):382-4 
Matsubara D, Kanai Y, Ishikawa S, Ohara S, Yoshimoto T, 
Sakatani T, Oguni S, Tamura T, Kataoka H, Endo S, 
Murakami Y, Aburatani H, Fukayama M, Niki T. 
Identification of CCDC6-RET fusion in the human lung 
adenocarcinoma cell line, LC-2/ad. J Thorac Oncol. 2012 
Dec;7(12):1872-6 
Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, 
Mack JS, Silver MR, Zhou X, Haack H. Analysis of 
receptor tyrosine kinase ROS1-positive tumors in non-
small cell lung cancer: identification of a FIG-ROS1 fusion. 
Clin Cancer Res. 2012 Aug 15;18(16):4449-57 
Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee 
J, Jung YJ, Kim JO, Shin JY, Yu SB, Kim J, Lee ER, Kang 
CH, Park IK, Rhee H, Lee SH, Kim JI, Kang JH, Kim YT. 
The transcriptional landscape and mutational profile of 
lung adenocarcinoma. Genome Res. 2012 
Nov;22(11):2109-19 
Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, 
Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski 
MF, Rizvi N, Khanin R, Ladanyi M. Identification of KIF5B-
RET and GOPC-ROS1 fusions in lung adenocarcinomas 
through a comprehensive mRNA-based screen for tyrosine 
kinase fusions. Clin Cancer Res. 2012 Dec 
15;18(24):6599-608 
Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, 
Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, 
Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, 
Ishikawa Y. RET, ROS1 and ALK fusions in lung cancer. 
Nat Med. 2012 Feb 12;18(3):378-81 
Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, 
Asaka R, Nakajima T, Mano H, Takeuchi K. KLC1-ALK: a 
novel fusion in lung cancer identified using a formalin-fixed 
paraffin-embedded tissue only. PLoS One. 
2012;7(2):e31323 
Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Luo X, Wang L, Li 
H, Zhang Y, Li F, Lu Y, Lu Q, Xu J, Garfield D, Shen L, Ji 
H, Pao W, Sun Y, Chen H. RET fusions define a unique 
molecular and clinicopathologic subtype of non-small-cell 
lung cancer. J Clin Oncol. 2012 Dec 10;30(35):4352-9 
Majewski IJ, Mittempergher L, Davidson NM, Bosma A, 
Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK, 






Atlas Genet Cytogenet Oncol Haematol. 2015; 19(4) 315 
Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, 
Kluin RJ, Brugman W, Kerkhoven R, Nieboer F, Roepman 
P, Broeks A, Muley TR, Jassem J, Niklinski J, van 
Zandwijk N, Brazma A, Oshlack A, van den Heuvel M, 
Bernards R. Identification of recurrent FGFR3 fusion genes 
in lung cancer through kinome-centred RNA sequencing. J 
Pathol. 2013 Jul;230(3):270-6 
Mo ML, Chen Z, Zhou HM, Li H, Hirata T, Jablons DM, He 
B. Detection of E2A-PBX1 fusion transcripts in human non-
small-cell lung cancer. J Exp Clin Cancer Res. 2013 May 
20;32:29 
Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada 
Y, Asamura H, Furuta K, Shibata T, Tsuda H. ROS1-
rearranged lung cancer: a clinicopathologic and molecular 
study of 15 surgical cases. Am J Surg Pathol. 2013 
Apr;37(4):554-62 
This article should be referenced as such: 
Huret JL. Lung: Translocations in Adenocarcinoma. Atlas 
Genet Cytogenet Oncol Haematol. 2015; 19(4):311-315. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
